<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Invasive cervical cancer: Patterns of recurrence and post-treatment surveillance</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Invasive cervical cancer: Patterns of recurrence and post-treatment surveillance</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Invasive cervical cancer: Patterns of recurrence and post-treatment surveillance</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Michael Straughn, Jr, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Despite screening programs that have dramatically reduced the incidence of cervical cancer in the United States, cervical cancer is the fourth most common cancer in women worldwide [<a href="#rid1">1</a>]. Squamous cell carcinoma (SCC) accounts for approximately 80 percent of cervical cancers, while adenocarcinoma accounts for 15 percent, and adenosquamous carcinoma for 3 to 5 percent; neuroendocrine or small cell carcinomas are rare. (See  <a class="medical medical_review" href="/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis"</a>.)</p><p>Management and outcomes for women with invasive cervical cancer depend upon the stage of disease at diagnosis  (<a class="graphic graphic_table graphicRef119447" href="/d/graphic/119447.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef139268" href="/d/graphic/139268.html" rel="external">table 2</a>). In general, primary treatment for cervical cancer (surgery or radiotherapy with or without chemotherapy) has a cure rate of approximately 80 to 95 percent in early-stage disease (stage I and nonbulky stage II disease) and approximately 40 to 60 percent for bulky stage II and stage III disease. A summary of survival rates by stage of disease according to International Federation of Gynecology and Obstetrics (FIGO) data is presented in the following table  (<a class="graphic graphic_table graphicRef64747" href="/d/graphic/64747.html" rel="external">table 3</a>) [<a href="#rid2">2</a>].</p><p>Post-treatment surveillance after primary curative therapy for cervical cancer is uniformly recommended, although its effectiveness is not well studied. The main goal of surveillance is early detection of those recurrences that might be amenable to potentially curative salvage therapy. This is most likely with isolated central pelvic recurrences.</p><p>The timing and location of recurrent disease following potentially curative treatment for cervical cancer, the published data on the effectiveness of various surveillance strategies, and recommendations for post-treatment surveillance are reviewed here. Staging and primary management of invasive cervical cancer, as well as the approach to women treated for cervical cancer, are discussed separately. (See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer"</a> and  <a class="medical medical_review" href="/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer"</a> and  <a class="medical medical_review" href="/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes"</a> and  <a class="medical medical_review" href="/d/html/13929.html" rel="external">"Invasive cervical adenocarcinoma"</a> and  <a class="medical medical_review" href="/d/html/17008.html" rel="external">"Overview of approach to cervical cancer survivors"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATTERNS OF RECURRENCE</span><span class="headingEndMark"> — </span>For women who underwent curative-intent therapy for cervical cancer, the predominant site of disease recurrence is local (ie, at the vaginal apex) or regional (ie, pelvic sidewall). The risk of persistent or recurrent pelvic disease increases with more advanced initial disease stage  (<a class="graphic graphic_table graphicRef119447" href="/d/graphic/119447.html" rel="external">table 1</a>). As an example, one series reported pelvic failure rates of 10, 17, 23, 42, and 74 percent among 322 women undergoing radiation therapy (RT) alone for stage IB, IIA, IIB, III, and IVA disease, respectively [<a href="#rid3">3</a>].</p><p>Retrospective studies have reported the following distribution of anatomic sites of recurrence [<a href="#rid4">4-7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Central (ie, vaginal apex or pelvis without sidewall involvement) – 22 to 56 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic sidewall – 28 to 37 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Distant metastases or multiple recurrence sites – 15 to 61 percent</p><p></p><p>The risk of recurrence is associated with well-known prognostic indicators, including tumor size and nodal involvement [<a href="#rid8">8</a>]. In one series including 1211 women undergoing RT alone, the 10-year actuarial incidence rates of distant metastatic disease in women with stage IA, IB, IIA, IIB, III, and IVA disease were 3, 16, 31, 26, 39, and 75 percent, respectively [<a href="#rid9">9</a>]. </p><p>Recurrence risk may also be associated with tumor histology, tumor grade, and lymphovascular space involvement (LVSI). In a retrospective study including 4343 women with cervical cancer, rates of recurrence were highest among those with the following [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Neuroendocrine tumors (hazard ratio [HR] 5.7, 95% CI 3.5-9.3) </p><p class="bulletIndent1"><span class="glyph">●</span>Tumors 2 to &lt;4 cm (HR 3.1, 95% CI 1.9-4.9) and ≥4 cm (HR 4.7, 95% CI 2.9-7.6) </p><p class="bulletIndent1"><span class="glyph">●</span>≥3 positive pelvic lymph nodes (HR 2.6, 95% CI 1.9-3.4) </p><p class="bulletIndent1"><span class="glyph">●</span>LVSI (HR 1.7, 95% CI 1.4-2.1)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Effect of mode of treatment</span><span class="headingEndMark"> — </span>The treatment approach to women with cervical cancer depends on whether their disease is early-stage or locally advanced. For women with early-stage disease, surgery is often the treatment of choice. However, the presence of intermediate or high-risk factors postoperatively may warrant additional treatment with RT. For patients with more locally advanced disease, treatment predominantly consists of chemoradiation (with or without a subsequent hysterectomy). These treatments may impact the risks and types of recurrence seen. (See  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer"</a> and  <a class="medical medical_review" href="/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer"</a>.)</p><p>Among patients treated for early-stage disease  (<a class="graphic graphic_table graphicRef119447" href="/d/graphic/119447.html" rel="external">table 1</a>), there appears to be no difference in either the rate or anatomic distribution of recurrences in surgically treated patients and patients who underwent surgery followed by RT [<a href="#rid4">4-7,11-14</a>]. This was best illustrated in a randomized trial of radical surgery versus RT for stage IB to IIA cervical cancer (although patients with high-risk factors after surgery also were treated with adjuvant RT) [<a href="#rid11">11</a>]. This study reported that there was no significant difference in the five-year patterns of recurrence in patients who received pelvic RT versus surgery alone [<a href="#rid11">11</a>]. </p><p>In addition, <strong>retrospective</strong> reports of patients receiving RT alone or in conjunction with surgery show similar distributions of site of recurrence as reports of patients treated with surgery alone. For example, one single-institution review included 334 patients, 41 (13.4 percent) of whom had gross nodal disease identified at the time of radical hysterectomy. Of these 41 patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Fifteen did not proceed with the hysterectomy and underwent lymphadenectomy alone. All patients were treated postoperatively with whole pelvic RT and vaginal brachytherapy (VBT). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Twenty-six patients underwent both radical hysterectomy and lymphadenectomy. Based on pathologic findings, 11 underwent whole pelvic RT, while eight proceeded with whole pelvic RT and VBT. </p><p></p><p>Compared with no radical hysterectomy, radical hysterectomy was not associated with significant differences in: </p><p class="bulletIndent1"><span class="glyph">●</span>The rate of local (11.5 versus 26.7 percent) or distant recurrence (19.2 versus 33.3 percent), respectively</p><p class="bulletIndent1"><span class="glyph">●</span>Progression-free survival (PFS, median, 74.9 versus 46.8 months)</p><p class="bulletIndent1"><span class="glyph">●</span>Overall survival (OS, 91.8 versus 69.4 months, p = 0.886)</p><p></p><p>For women with locally advanced disease, chemoradiation results in a lower risk of locoregional relapse. For example, in one trial the rate of relapse with RT alone was 34 percent, which was significantly higher than the rate of relapse after chemoradiation (18 percent) [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/3187.html" rel="external">"Management of locally advanced cervical cancer", section on 'Primary chemoradiation'</a> and  <a class="medical medical_review" href="/d/html/3246.html" rel="external">"Management of early-stage cervical cancer", section on 'Alternatives in select populations'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Symptomatology and timing</span><span class="headingEndMark"> — </span>The majority of locoregional and distant recurrences (75 percent in one review [<a href="#rid16">16</a>]) are symptomatic [<a href="#rid16">16</a>], and the median time to recurrence ranges from 7 to 36 months after primary treatment [<a href="#rid6">6-8,12,17-22</a>]. In a systematic review of the literature, 62 to 89 percent of cervical cancer recurrences were detected within two years of primary treatment, while by year 5, 89 to 99 percent of recurrent disease had been detected [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Prognosis in recurrent disease</span><span class="headingEndMark"> — </span>Prognosis in recurrent disease depends upon the site of recurrence and the ability to pursue potentially curative therapy, in addition to other factors. Favorable prognostic factors include a localized, central pelvic recurrence with no sidewall fixation, a disease-free interval greater than six months, and size of the recurrence less than 3 cm in diameter. (See  <a class="medical medical_review" href="/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer"</a>.)</p><p>Despite improvements in the management of metastatic cervical cancer, more than 90 percent of patients who develop a distant recurrence will die of their disease within five years [<a href="#rid23">23</a>]. However, a subset of patients with isolated pulmonary metastases might be eligible for a potentially curative resection. (See  <a class="medical medical_review" href="/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer"</a> and  <a class="medical medical_review" href="/d/html/2796.html" rel="external">"Surgical resection of pulmonary metastases: Outcomes by histology"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">SURVEILLANCE STRATEGIES</span><span class="headingEndMark"> — </span>Surveillance after primary curative therapy for cervical cancer is uniformly recommended, although its effectiveness is not well studied [<a href="#rid16">16,24,25</a>]. The concept of long-term surveillance for patients treated with curative intent is based on the premise that early detection of recurrence may lead to treatments that have lower morbidity and increase survival. Early detection of recurrence is aimed at treating patients with potentially curative salvage therapy. This is most likely in women who develop a central recurrence (ie, vaginal apex or pelvis without sidewall involvement), although cure of patients with isolated pulmonary metastases is also possible. (See  <a class="medical medical_review" href="/d/html/2796.html" rel="external">"Surgical resection of pulmonary metastases: Outcomes by histology"</a> and  <a class="medical medical_review" href="/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Limited metastatic disease'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Benefit of surveillance</span><span class="headingEndMark"> — </span>No prospective comparative studies have specifically addressed the efficacy of routine surveillance for asymptomatic women compared with symptom-based reassessment. Retrospective series suggest that early detection of a localized disease recurrence in asymptomatic women may provide a survival benefit, but the best way to identify these women is unclear [<a href="#rid12">12,13,17,26</a>].</p><p>One of these retrospective reports was an outcomes analysis of 1096 women with stage 1B cervical cancer; approximately half of the women were treated with primary surgery and the other women with primary radiation therapy (RT) alone [<a href="#rid17">17</a>]. The post-treatment surveillance strategy included physical and pelvic examination with cervicovaginal cytology every three months for one year, every four months during years 2 and 3, and every six months during years 4 and 5. A chest radiograph was performed at the end of year 1. Major findings were:</p><p class="bulletIndent1"><span class="glyph">●</span>Only 19 of 133 women who relapsed were asymptomatic at diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All pelvic recurrences (n = 37) were detected by pelvic exam; none were detected using cytology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prognostic factors associated with longer survival included asymptomatic disease, central pelvic, and/or pulmonary recurrences.</p><p></p><p>Although retrospective in nature, these data provide support for routine surveillance to detect recurrences at a time when they are still asymptomatic. The available modalities for post-treatment surveillance include history and physical examination, including pelvic examination, vaginal vault cytology (Pap smear), chest radiograph, computed tomography (CT) scans, pelvic ultrasound, intravenous pyelography (IVP), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. </p><p class="headingAnchor" id="H540597126"><span class="h2">Approach</span><span class="headingEndMark"> — </span>Multiple groups have issued guidelines for the follow-up after cervical cancer, including Cancer Care Ontario [<a href="#rid16">16</a>], the National Comprehensive Cancer Network [<a href="#rid24">24</a>], the American College of Obstetrics and Gynecology [<a href="#rid25">25</a>], and the Society of Gynecologic Oncology [<a href="#rid27">27</a>]. What follows below reflects our approach to surveillance as well as evidence to support various components of follow-up, which were also supported by a 2009 systematic review conducted by Cancer Care Ontario [<a href="#rid16">16</a>].</p><p>We follow the surveillance guidelines of the Society of Gynecologic Oncology [<a href="#rid27">27</a>]. These include:</p><p class="headingAnchor" id="H11"><span class="h3">History and physical examination</span><span class="headingEndMark"> — </span>We perform history and physical exams every six months for two years, every 6 to 12 months for up to five years, and then annually as the primary surveillance modality. Patients with high-risk disease can be followed more frequently (every three months) than patients with low-risk disease (six months). This is supported by the Cancer Care Ontario systematic review, which reported that physical examination (including pelvic, chest, and abdominal examination and careful lymph node survey) detected a median of 52 percent (range, 0 to 71 percent) of asymptomatic recurrences [<a href="#rid16">16</a>]. Symptoms that raise concern for a cervical cancer recurrence include: vaginal bleeding or discharge, abdominopelvic pain, urinary symptoms, and/or change in bowel habits.</p><p>Physical examination findings suspicious for recurrence include: enlarged lymph nodes, in particular groin or supraclavicular nodes; a vaginal lesion that is friable, raised, or nodular; nodularity in the rectovaginal septum; or a palpable mass at any location, most commonly in the pelvis.</p><p class="headingAnchor" id="H12"><span class="h3">Cervicovaginal cytology</span><span class="headingEndMark"> — </span>For women who have undergone RT, we do not perform cervicovaginal cytology routinely as part of surveillance because it is rarely helpful. However, for those patients who did not undergo RT (eg, those treated with primary hysterectomy for very early disease), annual cervical cytology should be performed [<a href="#rid27">27</a>]. </p><p>In the Cancer Care Ontario systematic review, a median of 6 percent (range, 0 to 16 percent) of asymptomatic recurrences were diagnosed based upon vaginal vault cytology [<a href="#rid16">16</a>]. It is possible that in patients who received RT, the accuracy of cervicovaginal cytology may be compromised by anatomic and tissue changes from RT, which lends more rationale not to obtain it.</p><p class="headingAnchor" id="H13"><span class="h3">Chest radiograph</span><span class="headingEndMark"> — </span>We do not perform chest radiographs in patients in the absence of symptoms. For the small number of women who develop an isolated pulmonary recurrence, early detection might increase the proportion who are considered candidates for potentially curative metastasectomy. However, data on this subset of women were not reported in the individual studies, and there are no data to address whether early detection and treatment of these patients increased their cure rate. (See  <a class="medical medical_review" href="/d/html/2796.html" rel="external">"Surgical resection of pulmonary metastases: Outcomes by histology"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">CT scan</span><span class="headingEndMark"> — </span>We do not routinely perform computed tomography (CT) scans for surveillance. The utility of CT as a method to detect asymptomatic recurrences has not been established, and there is no consensus on this. In the systematic review, between 0 and 34 percent of asymptomatic recurrences were diagnosed by CT [<a href="#rid16">16</a>]. </p><p class="headingAnchor" id="H16"><span class="h3">PET/CT scan</span><span class="headingEndMark"> — </span>Positron emission tomography (PET) in combination with computed tomography (CT; PET/CT) scans are often performed in the initial work-up and staging of cervical cancer and are used in surveillance after treatment. In patients at high risk for locoregional failure, we perform a PET/CT three to six months after therapy to detect early or asymptomatic recurrence, which may be curable. Additional radiologic studies can be performed to assess for recurrence when clinically indicated but not performed as routine surveillance. </p><p>Initial staging of cervical cancer is a United States Medicare-reimbursable indication for PET/CT scanning. PET/CT is a sensitive and specific method of detecting lymph node metastases in newly diagnosed cervical cancer, and most institutions perform a PET/CT scan during initial staging as an adjunct to conventional imaging. While a PET scan can be performed as a single modality, we only order it as part of a combined study with CT for better delineation of potential disease. However, we acknowledge that the diagnostic characteristics of PET versus PET/CT have not been formally evaluated and that much of the data evaluating this treatment modality are historically specific to PET alone [<a href="#rid28">28-32</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Other tests</span><span class="headingEndMark"> — </span>In the systematic review, all other studies, including ultrasound, MRI, and IVP were not of clinical benefit in detecting recurrent disease [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H2605530119"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113940.html" rel="external">"Society guideline links: Treatment of cervical cancer"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Surveillance after primary curative therapy for cervical cancer is uniformly recommended, although its effectiveness is not well studied. The main goal of surveillance is early detection of those recurrences that might be amenable to potentially curative salvage therapy. This is most likely in patients who have an isolated central pelvic recurrence. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal surveillance strategy has not been established. There is consensus on the need to perform clinical evaluation (a review of systems and physical examination). (See <a class="local">'Approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Careful clinical evaluation is the most important component of the follow-up for patients with cervical cancer (a review of systems and physical examination with particular attention to the supraclavicular and inguinal lymph nodes, as well as rectovaginal and abdominal examinations). (See <a class="local">'History and physical examination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For women who have undergone radiation therapy (RT), we do not perform cervicovaginal cytology routinely as part of surveillance because it is rarely helpful. However, for those patients who did not undergo RT (eg, those treated with primary hysterectomy for very early disease), annual cervical cytology should be performed. (See <a class="local">'Cervicovaginal cytology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging should not be routinely performed as part of surveillance in asymptomatic patients. (See <a class="local">'CT scan'</a> above and <a class="local">'PET/CT scan'</a> above.)</p><p></p><p class="headingAnchor" id="H10391022"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jennifer F De Los Santos, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (Accessed on January 15, 2014).</li><li><a class="nounderline abstract_t">Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S43.</a></li><li><a class="nounderline abstract_t">Perez CA, Grigsby PW, Camel HM, et al. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys 1995; 31:703.</a></li><li><a class="nounderline abstract_t">Muram D, Curry RH, Drouin P. Cytologic follow-up of patients with invasive cervical carcinoma treated by radiotherapy. Am J Obstet Gynecol 1982; 142:350.</a></li><li><a class="nounderline abstract_t">Rintala MA, Rantanen VT, Salmi TA, et al. PAP smear after radiation therapy for cervical carcinoma. Anticancer Res 1997; 17:3747.</a></li><li><a class="nounderline abstract_t">Gerdin E, Cnattingius S, Johnson P, Pettersson B. Prognostic factors and relapse patterns in early-stage cervical carcinoma after brachytherapy and radical hysterectomy. Gynecol Oncol 1994; 53:314.</a></li><li><a class="nounderline abstract_t">Morice P, Deyrolle C, Rey A, et al. Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy. Ann Oncol 2004; 15:218.</a></li><li><a class="nounderline abstract_t">Sartori E, Pasinetti B, Carrara L, et al. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. Gynecol Oncol 2007; 107:S241.</a></li><li><a class="nounderline abstract_t">Fagundes H, Perez CA, Grigsby PW, Lockett MA. Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1992; 24:197.</a></li><li><a class="nounderline abstract_t">Cibula D, Dostálek L, Jarkovsky J, et al. The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer. Eur J Cancer 2021; 158:111.</a></li><li><a class="nounderline abstract_t">Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350:535.</a></li><li><a class="nounderline abstract_t">Samlal RA, Van Der Velden J, Van Eerden T, et al. Recurrent cervical carcinoma after radical hysterectomy: an analysis of clinical aspects and prognosis. Int J Gynecol Cancer 1998; 8:78.</a></li><li><a class="nounderline abstract_t">Larson DM, Copeland LJ, Stringer CA, et al. Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol 1988; 30:381.</a></li><li><a class="nounderline abstract_t">Krebs HB, Helmkamp BF, Sevin BU, et al. Recurrent cancer of the cervix following radical hysterectomy and pelvic node dissection. Obstet Gynecol 1982; 59:422.</a></li><li><a class="nounderline abstract_t">Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004; 22:872.</a></li><li><a class="nounderline abstract_t">Elit L, Fyles AW, Devries MC, et al. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 2009; 114:528.</a></li><li><a class="nounderline abstract_t">Bodurka-Bevers D, Morris M, Eifel PJ, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000; 78:187.</a></li><li><a class="nounderline abstract_t">Esajas MD, Duk JM, de Bruijn HW, et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol 2001; 19:3960.</a></li><li><a class="nounderline abstract_t">Ansink A, de Barros Lopes A, Naik R, Monaghan JM. Recurrent stage IB cervical carcinoma: evaluation of the effectiveness of routine follow up surveillance. Br J Obstet Gynaecol 1996; 103:1156.</a></li><li><a class="nounderline abstract_t">Duyn A, Van Eijkeren M, Kenter G, et al. Recurrent cervical cancer: detection and prognosis. Acta Obstet Gynecol Scand 2002; 81:759.</a></li><li><a class="nounderline abstract_t">Beadle BM, Jhingran A, Yom SS, et al. Patterns of regional recurrence after definitive radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2010; 76:1396.</a></li><li><a class="nounderline abstract_t">Soisson AP, Geszler G, Soper JT, et al. A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy. Obstet Gynecol 1990; 76:106.</a></li><li><a class="nounderline abstract_t">Hong JH, Tsai CS, Lai CH, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:249.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Cervical cancer. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf (Accessed on May 05, 2020).</li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas. Number 35, May 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 78:79.</a></li><li><a class="nounderline abstract_t">Chou HH, Wang CC, Lai CH, et al. Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys 2001; 51:442.</a></li><li><a class="nounderline abstract_t">Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.</a></li><li><a class="nounderline abstract_t">Chung HH, Kim SK, Kim TH, et al. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis. Gynecol Oncol 2006; 103:165.</a></li><li><a class="nounderline abstract_t">Brooks RA, Rader JS, Dehdashti F, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2009; 112:104.</a></li><li><a class="nounderline abstract_t">Grigsby PW, Siegel BA, Dehdashti F, Mutch DG. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 2003; 55:907.</a></li><li><a class="nounderline abstract_t">Ryu SY, Kim MH, Choi SC, et al. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003; 44:347.</a></li><li><a class="nounderline abstract_t">Siva S, Herschtal A, Thomas JM, et al. Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. Cancer 2011; 117:3981.</a></li></ol></div><div id="topicVersionRevision">Topic 3227 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (Accessed on January 15, 2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17161167" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7860381" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7065026" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cytologic follow-up of patients with invasive cervical carcinoma treated by radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427773" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : PAP smear after radiation therapy for cervical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8206404" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prognostic factors and relapse patterns in early-stage cervical carcinoma after brachytherapy and radical hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760112" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17826824" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1526855" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Distant metastases after irradiation alone in carcinoma of the uterine cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34666213" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9284774" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11576287" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recurrent cervical carcinoma after radical hysterectomy: an analysis of clinical aspects and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3391421" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Recurrent cervical carcinoma after radical hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7078892" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Recurrent cancer of the cervix following radical hysterectomy and pelvic node dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14990643" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19560188" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Follow-up for women after treatment for cervical cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926801" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Posttherapy surveillance of women with cervical cancer: an outcomes analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579117" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8917006" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Recurrent stage IB cervical carcinoma: evaluation of the effectiveness of routine follow up surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12174162" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recurrent cervical cancer: detection and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19581056" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Patterns of regional recurrence after definitive radiotherapy for cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2359555" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337563" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recurrent squamous cell carcinoma of cervix after definitive radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337563" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recurrent squamous cell carcinoma of cervix after definitive radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12197489" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas. Number 35, May 2002. American College of Obstetricians and Gynecologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11567819" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752752" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16574205" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18929403" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12605968" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Posttherapy surveillance monitoring of cervical cancer by FDG-PET.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12620999" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21365626" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
